Raf kinase trapping to Golgi (RKTG) is reported to be a tumor suppressor in a number of solid tumors due to its negative modulation of the Ras/Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) pathways. However, the role of RKTG in the progression of leukemia remains unknown. In the present study, a human leukemia U937 cell line overexpressing RKTG was established, and the effect of RKTG on proliferation, cell cycle and apoptosis of human leukemia cells was analyzed. The results of the present study demonstrated that exogenous overexpression of RKTG significantly inhibited cell proliferation, which was accompanied by cell cycle arrest. Apoptosis assay and Hoechst staining demonstrated that the percentage of apoptotic cells in RKTG overexpressing cells was markedly increased. Furthermore, western blotting showed that RKTG overexpression significantly increased the level of cleaved caspase 3, B-cell lymphoma 2 (Bcl2)-associated X apoptosis regulator and reduced the level of Bcl-2. In addition, the activation of ERK and phosphoinositide 3-kinase/AKT serine/threonine kinase 1 signaling pathways in human leukemia cells was also suppressed by RKTG overexpression. In conclusion, the present study demonstrated the tumor-suppressive effect of RKTG on human leukemia cells, which seem to be partially dependent on the suppression of ERK and PI3K/AKT signaling. Overexpression of RKTG may be a potential therapeutic target for the treatment of leukemia.

Introduction

Acute myeloid leukemia (AML) is a heterogeneous group of neoplastic hematologic disorders characterized by differentiation arrest of hematopoiesis, which leads to uncontrolled proliferation and accumulation of clonal cells that are blocked at various steps of maturation (1,2). The main clinical symptoms of AML are anemia, hemorrhage, fever, lymphadenectasis and musculoskeletal pain (3). AML accounts for 3% of total incidences of malignant tumors. There are ~257,000 mortalities from leukemia annually worldwide (4). Despite considerable advances, chemotherapy remains the primary therapeutic approach for the treatment of leukemia, the prognosis remains poor and the 5-year survival rate has remained at 15-30% since the 1970s (2,5,6). It has been reported that genetic alterations are involved in leukemogenesis (7,8), thus manipulating myeloid maturation-associated genes may lead to potential therapies (9,10). Therefore, investigating the underlying molecular mechanisms is important for a comprehensive study of the progression of leukemia and for the identification of novel candidate targets for therapy.

Raf kinase trapping to Golgi (RKTG) is a member of progestin and adipoQ receptor family and also a membrane protein of the Golgi apparatus. Previous studies have reported that RKTG functions as a spatial regulator of Raf kinase by binding it to the Golgi apparatus. Therefore, RKTG has an inhibitory effect on Ras/Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling (11,12). The Ras/Raf/MEK/ERK signaling pathway is responsible for the extracellular signal transduction into the nucleus, therefore it has a pivotal role in regulation of fundamental cellular functions, including cell proliferation, apoptosis, metabolism and differentiation (13). Studies have demonstrated that RKTG can act as a tumor suppressor in human malignant melanoma cells (12), renal cell carcinoma (14), colorectal cancer (15), laryngeal squamous cell carcinoma (16) and osteosarcoma (17). Deletion of RKTG markedly increased the incidence of chemical carcinogen-induced tumorigenesis in the mouse skin (14). However, to the best of our knowledge, whether RKTG is implicated in the progress of leukemia remains to be investigated.

Correspondence to: Dr Hua Fan, Department of Hematology, The Fourth Affiliated Hospital of China Medical University, 4 East Chongshan Road, Shenyang, Liaoning 110032, P.R. China E-mail: adofcmu@163.com

Key words: acute myeloid leukemia, Raf kinase trapping to Golgi, proliferation, apoptosis, extracellular signal-regulated kinase, phosphatidylinositol 3-kinase/AKT serine/threonine kinase 1
In the present study, RKTG was exogenously expressed in the human leukemia cell line U937. The present study demonstrated for the first time to the best of our knowledge that RKTG is able to markedly impair cell viability and induce apoptosis of U937 cells. Furthermore, RKTG overexpression suppressed the activation of the ERK and phosphoinositide 3-kinase (PI3K)/AKT signaling pathways in the U937 cell line. In summary, the present study uncovered a tumor-suppressive effect of RKTG in leukemia cell lines.

Materials and methods

Cell culture. Human leukemia cell line U937 was obtained from the Cell Bank of Type Culture Collection Center of the Chinese Academy of Science (Shanghai, China). Cells were cultured with RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (HyClone; GE Healthcare Life Sciences, Logan, UT, USA), 100 U/ml penicillin and 100 µg/ml streptomycin at 37˚C in a humidified incubator with 5% CO2.

Plasmid construction and cell transfection. The coding sequence of RKTG was amplified by quantitative polymerase chain reaction (qPCR) using a forward primer, 5'-CGCAAGCTTATGCATGAGGCTGCTGA-3' and a reverse primer, 5'-CACGCTGAGTCAAAACAAGCA AATACAGGT-3'. The products were double digested by HindIII/XhoI restriction enzymes (Fermentas; Thermo Fisher Scientific, Inc., Pittsburgh, PA, USA) and inserted into the pcDNA3.1 plasmid by using UltraPower pUM-T fast clone kit (BioTek China, Beijing, China). Positive clones were screened by 100 µg/ml ampicillin and identified by automated sequencing. For transfection, U937 cells were seeded into 6-well plates at a density of 5x10^5 cells/well and grown to 70-80% confluence. The U937 cells were subsequently transfected with pcDNA3.1 vector or pcDNA3.1-RKTG using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc., CA, USA) according to the manufacturer's protocol. G418 (600 µg/ml) was added to the medium 48 h following transfection, and the stable transfected clones were selected for 2 weeks. Finally, RKTG expression in the stable transfected cell line was examined by qPCR and western blotting.

Reverse transcription (RT)-qPCR. Total RNA of the cells was extracted using RNApure Rapid Total RNA Extraction kit (BioTek China) and reverse transcribed by Super M-MLV Reverse Transcriptase (BioTek China). SYBR-Green-based qPCR was performed by using 2X Power Taq PCR MasterMix (BioTek China, Beijing, China). Total RNA was converted to cDNA using Super M-MLV reverse transcriptase (BioTek China). SYBR-Green-based qPCR was performed by using 2X Power Taq PCR MasterMix (BioTek China, Beijing, China). The relative levels of RKTG (A) mRNA and (B) protein were determined by quantitative polymerase chain reaction and western blotting. β-actin was employed as an internal control. Data are shown as the mean ± standard deviation of 3 repeats. *P<0.01 vs. cells transfected with pcDNA3.1. RKTG, Raf kinase trapping to Golgi.

Western blotting. Cells from the U937 group, pcDNA3.1 transfected group and RKTG transfected group were lysed by radioimmunoprecipitation assay buffer solution (Beyotime Institute of Biotechnology, Haimen, China). The concentration of total protein was measured using BCA protein assay kit (Beyotime Institute of Biotechnology). A total of 40 µg protein was subjected to 5, 10 or 13% SDS-PAGE and transferred onto polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA). Following blocking with 5% (m/v) fat-free milk, the membranes were incubated at 4˚C overnight with primary antibodies: Anti-RKTG (1:200; sc-161992; Santa Cruz Biotechnology, Inc.), anti-phosphorylated (p)-mitogen-activated protein kinase 1 (anti-p-ERK; 1:200; bs-1522R; BIOSS), anti-p-ERK (1:500; bs-2637R; BIOSS, Beijing, China), anti-GSK-3β (anti-p-GSK-3β; 1:200; sc-8312; Santa Cruz Biotechnology, Inc.), anti-β-actin (1:1,000; ab2302; Abcam, Cambridge, MA, USA), anti-AKT (1:200; sc-9166; Santa Cruz Biotechnology, Inc.), anti-AKT (1:500; bs-2637R; BIOSS, Beijing, China), anti-Erk (1:500; bs-1522R; BIOSS), anti-Bax (anti-Bax; BA0315; 1:400; Wuhan Boster Biological Technology, Ltd.), anti-Bcl-2 (anti-Bcl-2; 1:400; BA0412; Wuhan Boster Biological Technology, Ltd., Wuhan, China), anti-Bcl-2-associated X, apoptosis regulator (anti-Bax; BA0315; 1:400; Wuhan Boster Biological Technology, Ltd.), anti-phosphorylated (p)-mitogen-activated protein kinase 1 (anti-p-ERK; 1:500; bs-1522R; BIOSS, Beijing, China), anti-ERK (1:500; bs-2637R; BIOSS), anti-p-AKT serine/threonine kinase 1 (anti-p-AKT; 1:200; sc-135651; Santa Cruz Biotechnology, Inc.), anti-AKT (1:200; sc-8312; Santa Cruz Biotechnology, Inc.), anti-p-glycogen synthase kinase-3β (anti-p-GSK-3β; 1:200; sc-161757; 1:200; Santa Cruz Biotechnology, Inc.) or anti-GSK-3β (1:200; sc-9166; Santa Cruz Biotechnology, Inc.).

Figure 1. Overexpression of RKTG in U937 human leukemia cells. The relative levels of RKTG (A) mRNA and (B) protein were determined by quantitative polymerase chain reaction and western blotting. β-actin was employed as an internal control. Data are shown as the mean ± standard deviation of 3 repeats. *P<0.01 vs. cells transfected with pcDNA3.1. RKTG, Raf kinase trapping to Golgi.
Specific bands were detected by horseradish peroxidase conjugated goat anti-rabbit (1:5,000; A0208; Beyotime Institute of Biotechnology) or goat anti-mouse IgG (1:5,000; A0216; Beyotime Institute of Biotechnology) at 37˚C for 45 min and visualized using enhanced chemiluminescence (ECL) kit (Qihai Biotechnology, Shanghai, China).

**Cell-counting kit-8 (CCK-8) assay.** Cells from the U937 group, pcDNA3.1 transfected group and RKTG transfected group were seeded in 96-well plates (2x10³ cells/well) and cultured in a humidified atmosphere (5% CO₂) at 37˚C. The CCK-8 solution (Beyotime Institute of Biotechnology) was added at 0, 24, 48, 72 and 96 h prior to an additional 1 h incubation. The optical density values at 450 nm were subsequently measured with a microplate reader (ELx-800; BioTek Instruments, Inc., Winooski, VT, USA).

**Flow cytometry.** For cell cycle analysis, 1x10⁶ cells from each group were fixed by 70% ethanol at 4˚C for 2 h. Following washing with PBS twice, cells were re-suspended in 500 µl staining buffer and incubated with 25 µl propidium iodide (PI) (Wanleibio, Shenyang, China) at 37˚C for 30 min in the dark. Apoptotic cells were assessed by Annexin V-fluorescein isothiocyanate (FITC)/PI double-staining cell apoptosis kit (Nanjing KeyGen Biotech Co., Ltd., Nanjing, China) according to the manufacturer's instructions. Briefly, the cells were stained with 5 µl Annexin V-FITC and 5 µl PI for 15 min at room temperature in the dark. The proportion of cells in each cell cycle phase and apoptotic state was measured by flow cytometry (BD Accuri C6; BD Biosciences, Franklin Lakes, NJ, USA). Data were processed using matched Accuri CFlow Plus software (version 1.0.1727; BD Accuri Cytometers Inc., MI, USA).

**Hoechst staining.** Hoechst staining was performed using a Hoechst 33258 staining kit (Wanleibio). Briefly, cells from each group were plated in a 12-well plate with a coverslip at a density of 2x10⁴ cells/well and grown at 37˚C for 24 h. Following fixation with 4% paraformaldehyde for 20 min at room temperature, cells were stained with 2 µl/ml Hoechst staining solution and washed with phosphate buffer solution two times. The slides were mounted and apoptotic nuclei were observed under a fluorescence microscope (IX53; Olympus Corporation, Tokyo, Japan).

**Statistical analysis.** Statistical analysis was performed by SPSS version 16.0 software (SPSS, Inc., Chicago, IL, USA). Results are expressed as the mean ± standard deviation.
Differences between groups were compared by one-way analysis of variance followed by the least significant difference post hoc test. *P*<0.05 was considered to indicate a statistically significant difference.

**Results**

**Establishment of RKTG overexpressing human leukemia cell line.** To investigate the biological function of RKTG in the progression of leukemia, human leukemia cell line U937 was transfected either with pcDNA3.1-RKTG that contained the full-length coding sequence of RKTG or the vector pcDNA3.1, which served as a negative control. The G418-resistant clones were subsequently selected, and the expression of RKTG was determined by RT-qPCR and western blotting. As expected, in cells transfected with pcDNA3.1-RKTG, the level of RKTG mRNA was significantly upregulated compared with the pcDNA3.1-transfected group (3.43±0.35 vs. 0.95±0.12; *P*<0.01; Fig. 1A). In addition, the protein level of RKTG was also significantly increased following transfection with pcDNA3.1-RKTG compared with the pcDNA3.1-transfected group (3.04±0.33 vs. 1.10±0.11; *P*<0.01; Fig. 1B). The RKTG overexpressing leukemia cell line was subsequently maintained in culture medium containing 300 µg/ml G418 for further investigation.

**Overexpression of RKTG suppresses proliferation of human leukemia cells.** To evaluate the effect of RKTG on leukemia cell growth, proliferation rate and cell cycle was analyzed by CCK-8 assay and flow cytometry. As shown in Fig. 2A, compared with the control group, exogenous expression of RKTG significantly inhibited the proliferation of leukemia cells at 48, 72 and 96 h (*P*<0.01). Additionally, overexpression of RKTG significantly increased the percentage of G0/G1 phase cells (81.43±7.44% vs. 58.87±5.82%; *P*<0.05; Fig. 2B and C). However, the proportion of cells in G2/M phase was significantly reduced when compared with the pcDNA3.1 transfected group (7.24±5.21% vs. 23.73±2.57%; *P*<0.01; Fig. 2B and C). Collectively, these results indicate that RKTG overexpression induced cell cycle arrest and inhibited proliferation of human leukemia cells.
Overexpression of RKTG induces apoptosis of human leukemia cells. To investigate the role of RKTG in cell apoptosis, U937 cells from each experimental group were stained with Annexin V-FITC and PI. The cells were subsequently subjected to flow cytometry. The results demonstrated that overexpression of RKTG in leukemia cells resulted in a marked increase in the rate of apoptosis as compared with the negative control (33.80±5.81% vs. 6.54±1.22%; P<0.01; Fig. 3A). This finding was further verified by Hoechst staining, (Fig. 3B). Apoptotic nuclei were observed in the cells overexpressing RKTG, which were characterized by brilliant blue staining of the apoptotic bodies, but not in the other groups. Furthermore, several apoptosis-associated proteins were also examined, as shown in Fig. 3C and D. When compared with pcDNA3.1 group, the level of anti-apoptotic protein Bcl-2 was markedly decreased (P<0.01), whilst the levels of proapoptotic protein cleaved caspase 3 and Bax were significantly upregulated by RKTG overexpression (P<0.01, P<0.05).

Overexpression of RKTG suppresses ERK and PI3K/AKT signaling in human leukemia cells. To assess whether ERK or PI3K/AKT signaling pathways are implicated in the RKTG-associated anticancer effect in leukemia cells, the expression of the key components of these pathways was measured by western blotting. The results demonstrated that the levels of p-ERK, p-AKT and p-GSK-3β were all significantly reduced in RKTG overexpression cells when compared with the cells transfected with the vector alone (0.47±0.06 vs. 1.08±0.21; P<0.01; 0.52±0.07 vs. 1.01±0.06; P<0.01; 0.34±0.03 vs. 1.03±0.8; P<0.05; Fig. 4). Therefore, exogenous expression of RKTG suppressed the activation of ERK and PI3K/AKT signaling pathways in leukemia cells, which may be a molecular mechanism for how RKTG inhibits proliferation and induces apoptosis of leukemia cells.

Discussion

RKTG has been reported to be closely associated with the progression of different types of malignant cancer cells (14, 19). However, the role of RKTG in the proliferation and apoptosis of leukemia cells remains to be fully elucidated. In the present study, the exogenous overexpression of RKTG significantly inhibited cell proliferation, blocked cell cycle progression, induced apoptosis and suppressed the activation of ERK and PI3K/AKT signaling pathways in leukemia cells. These results have provided evidence that RKTG may be a tumor suppressor in human leukemia cells.

RKTG is a spatial regulator of Raf-1 (11) and acts as an antitumor factor due to its inhibitory activity on Raf/MEK/ERK signaling (12, 14, 20). RKTG expression in the colorectal cancer samples was significantly reduced compared with adjacent normal tissues. Furthermore, RKTG expression was inversely correlated with the tumor grade in colorectal cancer (15). The proliferation rate of colon cancer cells was inhibited by RKTG overexpression. By contrast, lentiviral-mediated knockdown of RKTG markedly increased the proliferation rate of colon cancer cells (15). In addition, overexpression of RKTG in A375 melanoma cells resulted in a reduction in growth rate and colony-forming activity (12). In accordance with these studies, the present study demonstrated that exogenous expression of RKTG suppressed the proliferation of human leukemia cells. RKTG overexpression resulted in an increase in the number of cells in the G0/G1 phase. Therefore, overexpression of RKTG may inhibit leukemia cell proliferation by arresting the cell cycle in G0/G1 phase.

Xie et al (20) reported that, when treated with chemical carcinogens, the number of apoptotic cells in RKTG-deficient mice was significantly reduced compared with the number of cells in wild-type mice. The apoptotic status of RKTG overexpressing leukemia cells was also examined in the present study.
The results demonstrated that upregulation of RKTG markedly promoted the apoptosis of leukemia cells. To further elucidate the potential mechanisms of RKTG-mediated apoptosis, the level of apoptosis-associated proteins was also determined. Caspase-3 is a pivotal executor of apoptosis. The activation and cleavage of caspase-3 is a marker of irreversible apoptosis (21). The antiapoptotic protein Bcl-2 and proapoptotic protein Bax are key regulators of mitochondrial-mediated apoptosis (22). In the present study, exogenous overexpression of RKTG strongly increased the levels of cleaved caspase 3 and Bax, and decreased the expression of Bcl-2, suggesting that RKTG is able to induce apoptosis in leukemia cells.

The activation of intracellular signaling pathways is a critical determinant of the biological outcome of cancer cells (23). Aberrant upregulation of the Raf/MEK/ERK and PI3K/AKT pathways is frequently observed in leukemia patients, and these changes are closely associated with poor prognosis (24-27). The inhibitory activity of RKTG on Raf/MEK/ERK signaling has been reported in several tumor cell lines (11,12,14,15,20). Additionally, the activation of the PI3K/AKT signaling pathway induced by Gβγ2 overexpression in monkey kidney fibroblast cells COS7 has been previously reported to be markedly abrogated by RKTG co-overexpression (28). The present study demonstrated that upregulation of RKTG significantly suppressed the activation of ERK and PI3K/AKT signaling pathways. Since the blockade of ERK or PI3K/AKT pathways is frequently observed in leukemia patients, and these pathways are associated with the inhibition of ERK and activation of PI3K/AKT pathways, partly by the suppression of ERK and PI3K/AKT signaling pathways.

In summary, the results of the present study demonstrate that overexpression of RKTG is able to inhibit cell proliferation, induce cell cycle arrest and cause apoptosis of leukemia cells. These effects of RKTG in leukemia cells may be associated with the inhibition of ERK and activation of PI3K/AKT signaling. These findings indicate that overexpression of RKTG may serve as a promising strategy for the treatment of leukemia.

References